Abstract: A retaining system which may be used for locking an energy store, in particular for an electrically operable two-wheeled vehicle. The retaining system is designed such that it does not transfer any forces from the energy store to the retaining system in the locked or latched position.

Abstract: The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof.

Abstract: A lock system for securing a battery of a vehicle operable by muscle power and/or motor power, in particular an electric bicycle. The lock system includes: a deadbolt which is pivotable about a bolt axis, a lock cylinder which is configured to actuate the deadbolt, and a lifting element which is coupled to the lock cylinder, the lock cylinder being movable into a holding position and into a release position, the lock cylinder in the holding position preventing a removal of the battery in a removal direction, and in the release position allowing the removal of the battery. The lifting element is configured to move the battery in the removal direction when the deadbolt is moved from the holding position into the release position.

Abstract: An abrasion-resistant wood-based panel having a top side and a bottom side, with at least one decorative layer arranged on the top side, in particular with a structure synchronous with the decoration, is disclosed herein.

Abstract: A drive unit of a vehicle includes a motor and a crankshaft mechanically coupled by a transmission and located within a housing. The transmission includes a first gear wheel rotatable about a motor axis and a second gear wheel rotatable about a crank axis. The housing includes a first fastening region and a second fastening region, configured for fastening the drive unit to a frame interface of the vehicle, wherein, in a cutting plane through the drive unit and orthogonally to the crank axis, a longitudinal axis is defined that intersects the crank axis and the motor axis, and a first line is defined that is orthogonal to the longitudinal axis and tangential on an outer circumference of the motor, and wherein the first fastening region has a first center point arranged on the first line or on a side of the first line facing away from the crank axis.

Abstract: A frame assembly of a two-wheeled vehicle, operable with muscle power and/or motor power. The frame assembly includes a main frame, a sprung rear triangle, and at least one connecting element, which is arranged on the main frame. The connecting element connecting at least a part of the rear triangle to the main frame so as to be pivotable about a joint axis, and the connecting element being equipped for mounting a drive unit on the main frame.

Abstract: A drive assembly of a vehicle operable with muscular power and/or motor power. The drive assembly includes: a drive unit; a frame interface, the drive unit being arranged at least partially between a first wall and a second wall of the frame interface, the drive unit including a through-hole; two sleeves inserted into the through-hole of the drive unit on both sides; and a through-bolt inserted through the through-hole and the two sleeves and holding the drive unit on each of the two walls.

Abstract: A drive system of a vehicle which is operable using muscular energy and/or motor power. The drive system includes a drive unit and a frame interface, the drive unit being at least partially situated between a first wall and a second wall of the frame interface. The drive system further includes a holding device, which holds the drive unit on each of the two walls, the holding device being fixed in place on the second wall; and a tolerance compensation element. The first wall has a first wall opening. The tolerance compensation element is developed in the form of a sleeve and is situated inside the first wall opening. A part of the holding device is disposed inside the tolerance compensation element in an axially movable manner.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: An abrasion-resistant wood-based panel having a top side and a bottom side, with at least one decorative layer arranged on the top side, in particular with a structure synchronous with the decoration, is disclosed herein.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: A method for producing an abrasion-resistant wood-based panel having a top side and a bottom side, with at least one decorative layer arranged on the top side, in particular with a structure synchronous with the decoration, is disclosed herein.

Abstract: A method for producing an abrasion-resistant wood-based panel having a top side and a bottom side, with at least one decorative layer arranged on the top side, in particular with a structure synchronous with the decoration, is disclosed herein.

Abstract: A lock system for securing a battery of a vehicle operable by muscle power and/or motor power, in particular an electric bicycle. The lock system includes: a deadbolt which is pivotable about a bolt axis, a lock cylinder which is configured to actuate the deadbolt, and a lifting element which is coupled to the lock cylinder, the lock cylinder being movable into a holding position and into a release position, the lock cylinder in the holding position preventing a removal of the battery in a removal direction, and in the release position allowing the removal of the battery. The lifting element is configured to move the battery in the removal direction when the deadbolt is moved from the holding position into the release position.

Abstract: The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment.

Abstract: A retaining system which may be used for locking an energy store, in particular for an electrically operable two-wheeled vehicle. The retaining system is designed such that it does not transfer any forces from the energy store to the retaining system in the locked or latched position.

Abstract: The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof.

Abstract: A retaining element provided for two-stage fastening to an accumulator or which is part of an accumulator, safeguards against removal from a retaining device. The retaining device is oriented toward the retaining element and is fastened in an interior of tubes of a bicycle frame of an electrically driven bicycle.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.